Alexion Pharmaceuticals and Zealand Pharma are collaborating to discover and develop novel peptide therapies for complement-mediated diseases. Peptides offer a number of advantages, including being highly selective and potent, allowing low dosage volumes for ease of administration, and having the potential to treat a broad range of complement-mediated diseases… more
Separately, Alexion and Affibody AB have announced a partnership to co-develop ABY-039 for rare Immunoglobulin G-mediated autoimmune diseases. Currently in Phase 1 development, ABY-039 is a bivalent antibody-mimetic that targets the neonatal Fc receptor. ABY-039 has been specifically designed to combine Affibody’s protein therapeutics platform (Affibody® molecules) and Albumod™ technology to achieve a long half-life… more